A SWOG trial shows bortezomib, lenalidomide, and dexamethasone delays recurrence and lengthens life for myeloma patients, indicating a possible new standard of care.
SWOG is a publicly funded worldwide network of researchers who design and conduct cancer clinical trials. The Group’s goal is to change medical practice so it improves the lives of people with cancer. The approximately 6,000 physician-researchers in the network practice at more than 950 institutions nationwide and in six other countries. SWOG is part of the NCI’s National Clinical Trials Network and is supported primariliy through NCI research funding.